Do you have "refractory", treatment-resistant rheumatoid arthritis (RA)?

If so, you may be eligible for a study for a new therapy to help people like you. Participation in this study will not come at an additional cost to you.


This study, called the Frontier Study, is supported by Amgen.

Visit the Study Website

Or learn a little more about this study below.

What is the purpose of the Frontier Study?

This study aims to assess the effectiveness of a study drug and how it impacts RA symptoms, particularly in people with RA who have not responded well to other treatments.


Do I qualify to participate in this study?

You may be eligible to participate in this study if you:



  • Are between the ages of 18 - 75 years old
  • Have a confirmed diagnosis of rheumatoid arthritis
  • Have been told by your doctor that your rheumatoid arthritis is refractory*


*‘Refractory’ means your rheumatoid arthritis does not respond to standard treatment options or improve despite trying different medications.


You may not be eligible for this study if you:



  • Have other current inflammatory joint disease other than RA
  • Have had any type of organ transplant


Other eligibility criteria apply and will be evaluated by a study doctor if you choose to continue with screening for the study.

Where are the clinical sites?

  • United States

    • Columbia University Medical Center
    • MetroHealth Medical Center
    • Northwell Health
    • University of California Irvine
    • University of Colorado
    • University of California Los Angeles
    • University of Rochester Medical Center
    • Emory University
    • Johns Hopkins University
    • Mayo Clinic
    • University of Pittsburgh Medical Center
    • Massachusetts General Hospital
    • Seattle Rheumatology
    • Cleveland Clinic Foundation
    • University Medical Center New Orleans
    • Augusta University
    • University of Arizona, Arizona Arthritis Center
    • Northwell Health
    • Boston University School of Medicine
    • New York Medical College

  • Australia

    • St. Vincent's Hospital Sydney
    • Linear Clinical Research Limited
    • Royal Prince Alfred Hospital
    • Fiona Stanley Hospital

  • Belgium

    • Centre Hospitalier Universitaire de Liege - Sart Tilman
    • Cliniques Universitaire Saint Luc Université Catholique de Louvain
    • Universitaire Ziekenhuis Gent
    • Universitaire Ziekenhuis Leuven - Campus Gasthuisberg

  • Canada

    • William Osler / Brampton Civic

  • France

    • Hospital Europeen Georges Pompidou
    • Centre Hospitalier Universitaire de Lyon - Hôpital Edouard Herriot
    • Hôpital de la Conception
    • Hôpital Bichat Claude Bernard
    • Centre Hospitalier Universitaire de Strasbourg - Nouvel Hôpital Civil
    • Centre Hospitalier Universitaire de Toulouse - Hôpital Rangueil
    • Centre Hospitalier Regional Universitaire de Lille - Hôpital Claude Huriez
    • Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre
    • Centre Hospitalier Universitaire de Strasbourg - Hôpital de Hautepierre
    • Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan
    • Hôpital Cochin

  • Germany

    • Klinikum der LMU Muenchen
    • Universitaetsklinikum Leipzig
    • Universitaetsklinikum Duesseldorf AoeR
    • Krankenhaus Porz am Rhein gGmbH
    • Johannes Wesling Klinikum Minden

  • Italy

    • IRCCS Ospedale San Raffaele
    • IRCCS Istituto Clinico Humanitas
    • Ospedale San Giovanni Bosco
    • Azienda Universitaria Ospedaliera Consorziale Policlinico Bari

  • Portugal

    • Unidade Local de Saude de Lisboa Ocidental, EPE - Hospital Santa Cruz
    • Unidade Local de Saude de Gaia-Espinho, EPE

  • Spain

    • Hospital Universitario 12 de Octubre
    • Hospital Clinic i Provincial de Barcelona
    • Hospital Universitari Vall d Hebron
    • Hospital Universitario Marques de Valdecilla

  • United Kingdom

    • Addenbrookes Hospital
    • Leicester General Hospital
    • Freeman Hospital
    • Western General Hospital
    • Musgrave Park Hospital
    • Guys Hospital

What should I expect?

1. Submit Online Questionnaire 

This questionnaire will ask for your contact information and a few questions about your medical history to determine your eligibility. Then, select a time for a short phone call with PatientWing. Submitting the questionnaire is voluntary and does not require a commitment to participate in the study.

2. Speak With PatientWing

PatientWing is helping to identify potential individuals who may be interested in the Frontier Study.
You will have a short call with PatientWing to answer additional questions about your medical history and PatientWing will help collect your medical records.

3. Speak With a Research Site Representative

After your conversation with PatientWing, you will meet the research team who will review your medical records. If the research team thinks you are eligible, they will schedule a screening visit. The research team will provide more information during your conversations with them. No question is a bad question, so please share your concerns with the team!

4. Study Participation

After you've completed the screening period, the research team will notify you about your eligibility. If you are enrolled in the study, you should expect the following:

  • You will visit the study site approximately 20 times over 12 months.
  • You will have follow-up visits with the study team to investigate your response to the study drug.

Frequently Asked Questions (FAQ) about this study

  • How do I get started?

    Fill out the questionnaire and provide basic information to express interest in the study. You can also email studies@patientwing.com or call/text: 213-459-2979.

  • How is PatientWing involved in this clinical study process?

    We partner with study sponsors to match individuals with clinical studies. Our dedicated team provides clear information about available studies, connects you with research sites, and ensures you have the resources and guidance you need at every step. We are here to support your journey with clinical research!

  • How will the study drug be taken?

    The study drug will be given as subcutaneous injection once a week.

  • Will I be reimbursed for travel related costs?

    Expenses such as travel and parking are reimbursed within reasonable limits.

  • How often do I need to visit the research site?

    You will have 20 visits to the research site during the study period.

  • How long will the study take place?

    Your participation may be about 13 months.

  • Is there a chance I will receive a placebo?

    No, this study does not have a placebo. You will receive the study drug, blinatumomab, if you participate in the study.

  • Is there a tool I can use to determine if this study is right for me?

    YES! AiArthritis created a tool that can help you, your loved ones, and your doctor decide if a clinical trial is right for you. 


    You can download this on our main clinical trials page, as well as more guidance about clinical trial participate generally.

This study is affiliated with Amgen.